Equities analysts expect Coherus Biosciences Inc (NASDAQ:CHRS) to report ($0.90) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Coherus Biosciences’ earnings. Coherus Biosciences reported earnings of ($1.71) per share during the same quarter last year, which would indicate a positive year over year growth rate of 47.4%. The business is expected to issue its next earnings report on Monday, March 12th.
On average, analysts expect that Coherus Biosciences will report full year earnings of ($4.39) per share for the current fiscal year, with EPS estimates ranging from ($4.55) to ($4.23). For the next year, analysts expect that the firm will post earnings of ($2.91) per share, with EPS estimates ranging from ($3.10) to ($2.71). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Coherus Biosciences.
Coherus Biosciences (NASDAQ:CHRS) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.09) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%.
A number of institutional investors and hedge funds have recently modified their holdings of CHRS. Temasek Holdings Private Ltd acquired a new position in Coherus Biosciences in the third quarter valued at approximately $87,524,000. UBS Asset Management Americas Inc. lifted its stake in Coherus Biosciences by 54.5% in the second quarter. UBS Asset Management Americas Inc. now owns 1,391,216 shares of the biotechnology company’s stock valued at $19,964,000 after buying an additional 490,899 shares during the period. TIAA CREF Investment Management LLC lifted its stake in Coherus Biosciences by 70.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,001,104 shares of the biotechnology company’s stock valued at $14,366,000 after buying an additional 414,229 shares during the period. State Street Corp lifted its stake in Coherus Biosciences by 26.8% in the second quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock valued at $20,329,000 after buying an additional 298,986 shares during the period. Finally, Macquarie Group Ltd. lifted its stake in Coherus Biosciences by 551.1% in the second quarter. Macquarie Group Ltd. now owns 310,923 shares of the biotechnology company’s stock valued at $4,462,000 after buying an additional 263,168 shares during the period. 81.00% of the stock is currently owned by hedge funds and other institutional investors.
Coherus Biosciences (NASDAQ CHRS) opened at $11.95 on Tuesday. The company has a quick ratio of 5.46, a current ratio of 5.46 and a debt-to-equity ratio of 1.84. The company has a market capitalization of $692.45, a P/E ratio of -2.20 and a beta of 3.89. Coherus Biosciences has a 12 month low of $8.05 and a 12 month high of $28.60.
COPYRIGHT VIOLATION WARNING: “Brokerages Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share” was reported by BBNS and is the property of of BBNS. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://baseballnewssource.com/markets/brokerages-expect-coherus-biosciences-inc-chrs-will-post-earnings-of-0-90-per-share/1820429.html.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.